Pathogenesis, etiology and epidemiology of myelodysplastic syndromes

Haematologica

Volumn 83, Issue 1, 1998, Pages 71-86

  Aul, Carlo ^a   Bowen, David T ^b   Yoshida, Yataro ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Dundee Teaching Hospitals   (United Kingdom)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Alkylating agents; Apoptosis; Benzene; Clonality; Environmental and occupational toxins; Etiology; Genetic factors; Geriatric medical care; Incidence; Myelodysplastic syndromes

Indexed keywords

BENZENE; CIGARETTE SMOKE; COPPER; FERTILIZER; GASOLINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROGEN PEROXIDE; INTERLEUKIN 6; ORGANOHALOGEN DERIVATIVE; PESTICIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AGE DISTRIBUTION; APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CLONOGENESIS; CYTOKINE PRODUCTION; DNA REPAIR; GENE MUTATION; HUMAN; IONIZING RADIATION; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; REVIEW; SEX RATIO; TUMOR PROMOTION;

ANIMALS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0031906395     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma 1995; 16:247-62.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
3. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis. A distinct clinico-pathological entity. Br J Haematol 1991; 78:161-6.
4. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome. Incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993; 66:117-22.
5. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6:52-9.
6. Ito T, Ohashi H, Kagami Y, Ichikawa A, Saito H, Hotta T. Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy. Leukemia 1994; 8:839-43.
7. Aman K, Ito M, Misawa M, et al. Clonal analysis of peripheral blood and haematopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene. Br J Haematol 1995; 89:838-44.
8. Gallagher A, Darley RL, Padua RA. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82:191-204.
9. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Hematol 1993; 57:87-97.
10. Stephenson J, Mufti GJ, Yoshida Y. Myelodysplastic syndromes from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. Int J Hematol 1993; 57:99-112.
11. Delforge M, Demuynck H, Vandenberghe P, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995; 86:3660-7.
12. Richert-Boe KE, Bagby GC. In vitro hematopoiesis in myelodysplasia. Liquid and soft-gel culture studies. Hematol Oncol Clin N 1992; 6:543-56.
13. Paquette R, Koeffler HP. Myelodysplastic syndrome. Culture studies and their implications for therapy. In: Mufti GK, Galton DAG, eds. The myelodysplastic syndromes. Edinburgh: Churchill Livingstone, 1992:197-206.
14. Yoshida Y, Yoshida C, Tohyama K, et al. Prognostic implication of sequential bone marrow cultures in the myelodysplastic syndromes. Leuk Res 1989; 13:967-72.
15. + cells. Blood 1995; 85:194-202.
16. Aul C, Arning M, Runde V, Schneider W. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res 1991; 15:571-5.
17. Herold M, Schmalzl F, Zwierzina H. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res 1992; 16:585-8.
18. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996; 20:891-900.
19. Ohmori M, Ohmori S, Ueda Y, et al. Ineffective hematopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. Int J Cell Cloning 1991; 9:521-30.
20. Yoshida Y. Hypothesis. Apoptosis may be the mechanism responsible for the intramedullary cell death in myelodysplasia. Leukemia 1993; 7:144-6.
21. Anzai N, Kawabata H, Hirama T, et al. Marked apoptosis of human myelomonocytic cell line P39. Significance of cellular differentiation. Leukemia 1994; 8:446-53.
22. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268-76.
23. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia. The correlate of ineffective hematopoiesis. Leuk Lymphoma 1990; 2:415-8.
24. Lepelley P, Campergue L, Gradel N, et al. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 1996; 95:368-71.
25. Rajapaksa R, Ginzton N, Rott LS, et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275-87.
26. Larson CJ. The BCL-2 gene, prototype of a gene family that controls programmed cell death (apoptosis). Ann Genet 1994; 37:121 -34.
27. Hellstrom-Lindberg E, Kanter-Lewensohn L, Öst A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997; 21:415-25.
28. Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe b-thalassemia (Cooley's anemia). Blood 1993; 82:374-7.
29. Koury MJ, Horne DW. Apoptosis mediates and thymidine prevents erythroblast destruction in folate deficiency anemia. Proc Natl Acad Sci USA 1994; 91:4067-71.
30. Muta K, Kranz SB. Inhibition of heme synthesis induces apoptosis in human erythroid progenitor cells. J Cell Physiol 1995; 163:38-50.
31. Raza A, Mundle S, Shetty V. Novel insight into the biology of myelodysplastic syndromes. Excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265-78.
32. Koury MJ. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 1992; 20:391-4.
33. Yoshida Y, Anzai N, Kawabata H. Apoptosis in normal and neoplastic hematopoiesis. Crit Rev Oncol Hemat 1996; 24:185-211.
34. +-independent endonuclease activity capable of producing nucleosomal-size DNA fragmentation in non-adherent marrow mononuclear cell nuclei from patients with myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1996; 10:67-73.
35. +-dependent endonuclease in marrow CD34 positive and erythroid cells in myelodysplasia. Leuk Res (in press).
36. + cells and their granulocytic descendants. Blood 1995; 86:917-23.
37. Anzai N, Kawabata H, Hishita T, et al. Distribution of endogenous endonuclease activities capable of producing internucleosomal DNA fragmentation in nematopoietic cells. Int J Hematol (in press).
38. +-dependent endonuclease activities of human myeloid leukemia cells capable of producing nucleosomal-size DNA fragmentation. Biochem Biophys Res Comm 1997; 233:133-8.
39. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52.
40. Wilman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259:968-71.
41. Harada H, Kitagawa M, Tanaka N, et al. Anti-oncogenic and oncogenic potential of interferon regulatory factors 1 and 2. Science 1993; 259:971-4.
42. Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 1997; 82:364-70
43. Yin JAL, Geary CG, Love EM, Bhavnani M, Testa NG. Familial myelodysplasia. Br J Haematol 1987; 66: 418-9.
44. Lucas GS, West RR, Jacobs A. Familial myelodysplasia. Br Med J 1989; 299:551.
45. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330:597-601.
46. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995; 9:1569-72.
47. Socié G, Mary JY, Degramont A, et al. Paroxysmal nocturnal hemoglobinuria - long-term follow-up and prognostic factors. Lancet 1996; 348:573-7.
48. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253-8.
49. Van Kamp H, Smit JW, Vandenberg E, Halie MR, Vellenga E. Myelodysplasia following paroxysmal nocturnal hemoglobinuria. Evidence for the emergence of a separate clone. Br J Haematol 1994; 87:399-400.
50. Jin JY, Tooze JA, Marsh JCW, Matthey F, Gordon-Smith EC. Myelodysplasia following aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome after treatment with immunosuppression and G-CSF. Evidence for the emergence of a separate clone. Br J Haematol 1996; 894:510-2.
51. Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993; 329:1152-7.
52. Moloney WC. Radiogenic leukemia revisited. Blood 1987; 70:905-8.
53. Kadhim MA, Lorimore SA, Hepburn MD, Goodjead DT, Buckle VJ, Wright EG. Alpha particle-induced chromosomal instability in human bone marrow cells. Lancet 1994; 344:987-8.
54. Matsuo T, Tomonaga M, Bennett JM, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol 1988; 18:91-6.
55. West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res 1995; 19:127-39.
56. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7:1956-86.
57. Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Bailliere's Clin Haematol 1996; 9:57-85.
58. Pedersen-Bjergaard J, Larsen SO, Struck J, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents and time from chemotherapy. Lancet 1987; 2:83-8.
59. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer I 1994; 86:1450-7.
60. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12:2527-34.
61. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337:61-6.
62. Kaldor JM, Day WE, Clarke EA, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322:1-6.
63. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316:710-4.
64. Cachia PG, Taylor C, Thompson PW, et al. Non-dysplastic myelodysplasia. Leukemia 1994; 8:677-81.
65. Benyehuda D, Krichevsky S, Caspi O, et al. Micro-satellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88:4296-303.
66. Kaneko H, Horiike S, Taniwaki M, Misawa S. Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-β receptor type-II gene mutation. Leukemia 1996; 10:1696-9.
67. Nisse C, Lorthois C, Dorp V, Eloy E, Haguenoer JM, Fenaux P. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia 1995; 9:693-9.
68. Goldberg H, Lusk E, Moore J, Nowell PC, Besa EC. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome. Correlation with chromosomal patterns and data on patients without hematological disease. Cancer Res 1990; 50:6876-81.
69. Mele A, Szklo M, Visani G, et al. Hair dye use and other risk factors for leukemia and pre-leukemia: a case-control study. Am J Epidemiol 1994; 139:609-19.
70. Ido M, Nagata C, Kawakami N, et al. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 1996; 20:727-31.
71. Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia: a meta-analysis. Arch Intern Med 1993; 153:469-75.
72. Pasqualetti P, Festuccia V, Acitelli P, Collacciana A, Giusti A, Casale R. Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol 1997; 97:659-62.
73. Aksoy M, Dincol K, Erdem S, Dincol G. Acute leukemia due to chronic exposure to benzene. Am J Med 1972; 52:160-6.
74. Travis LB, Li CY, Zhang ZN, et al. Hematopoietic malignancies and related disorders among benzene-exposed workers in China. Leuk Lymphoma 1994; 14:91-102.
75. Yin SN, Hayes RB, Linet MS, et al. An expanded cohort study of cancer among benzene-exposed workers in China. Environ Health Persp 1996; 104:1339-41.
76. Cowles SR, Bennett JM, Ross CE. Medical surveillance for leukemia at a petrochemical manufacturing complex: four-year summary. J Occup Med 1991; 33:808-12.
77. Honda Y, Delzell E, Cole P. An updated study of mortality among workers at a petroleum manufacturing plant. J Occup Environ Med 1995; 37:194-200.
78. Cullen MR, Solomon LR, Pace PE, et al. Morphologic, biochemical, and cytogenetic studies of bone marrow and circulating blood cells in painters exposed to ethylene glycol ethers. Environ Res 1992; 59:250-64.
79. Rothman N, Smith MT, Hayes RB, et al. An epidemiologic study of early biologic effects of benzene in Chinese workers. Environ Health Persp 1996; 104:1365-70.
80. Ross D. Metabolic basis of benzene toxicity. Eur J Haematol 1996; 57:111-8.
81. Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for haematological malignancy, is associated with the NQO1 608C->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997; 57:2839-42.
82. Yardley-Jones A, Anderson D, Parke DV. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. Br J Ind Med 1991; 48:437-44.
83. Hiraku Y, Kawanishi S. Oxidative DNA damage andapoptosis induced by benzene metabolites. Cancer Res 1996; 56:5172-8.
84. Smith MT. Overview of benzene-induced aplastic anaemia. Eur J Haematol 1990; 60:107-10.
85. Anderson D, Hughes JA, Cebulskawasilewska A, Wierzewska A, Kasper E. Biological monitoring of workers exposed to emissions from petroleum plants. Environ Health Persp 1996; 104:609-13.
86. Smith MT, Rothman N, Yin S, et al. Benzene exposure and risk of MDS/AML Leuk Res 1997; 21 (Suppl 1):S3
87. Taylor JA, Sandler DP, Bloomfield CD, et al. RAS oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84:1626-32.
88. Mills NE, Hayes RB, Fishman CL, et al. RAS mutations in Chinese patients with benzene-associated and de novo acute leukemia. Blood 1994; 84:A47
89. Rothman N, Haas R, Hayes RB, et al. Benzene induces gene-duplicating but not gene-inactivating mutations at the glycophorin A locus in exposed humans. Proc Natl Acad Sci USA 1995; 92:4069-73.
90. Kyoizumi S, Nakamura N, Hakoda M, et al. Detection of somatic mutations at the glycophorin-A locus in erythrocytes of atomic-bomb survivors using a single beam flow sorter. Cancer Res 1989; 49:581-8.
91. Bigbee WL, Wyrobek AJ, Langlois RG, Jensen RH, Everson RB. The effect of chemotherapy on the in vivo frequency of glycophorin-A null variant erythrocytes. Mutat Res 1990; 240:165-75.
92. Binkova B, Lewtas J, Miskova I, et al. Biomarker studies in northern Bohemia. Environ Health Persp 1996; 104(Suppl 3):591-7.
93. Perera FP, Hemminki K, Gryzbowska E, et al. Molecular and genetic damage in humans from environmental pollution in Poland. Nature 1992; 360:256-8.
94. Hasle H. Myelodysplastic syndromes in childhood - classification, epidemiology, and treatment. Leuk Lymphoma 1994; 13:11-26.
95. Chessells JM. Myelodysplasia. Bailliere's Clin Haematol 1991; 4:459-82.
96. Goasguen JE, Bennett JM. Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol 1992; 19:4-13.
97. Fenaux P, Preudhomme C, Estienne MH, et al. De novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. Leuk Res 1990; 14:1053-9.
98. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82:358-67.
99. Ribera JM, Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br J Haematol 1987; 65:307-11.
100. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet Cytogen 1985; 17:189-225.
101. World Health Organization. International classification of disease, 9th revision. Geneva: World Health Organization; 1977.
102. Reizenstein P, Dabrowski L Increasing prevalence of the myelodysplastic syndromes. An international Delphi study. Anticancer Res 1991; 11:1069-70.
103. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995; 54:153-6.
104. Maynadié M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndromes in a well-defined French population. Br J Cancer 1996; 74:288-90.
105. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87:743-5.
106. Cartwright RA. Incidence and epidemiology of the myelodysplastic syndromes. In: Mufti GK, Galton DAG, eds. The myelodysplastic syndromes. Edinburgh: Churchill Livingstone; 1992. p. 23-31.
107. Saarni MI, Linman JW. Preleukemia: the hematologic syndrome preceding acute leukemia. Am J Med 1973; 55:38-48.
108. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin N Am 1993; 7:81-107.
109. Frank-Stromborg M. Changing demographics in the United States. Implications for health professionals. Cancer 1991; 67:1772-8.